Clinical Trials Browser

Expanded_access × Genitourinary × 90 days × Clear all

NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT06810141 2026-05-14

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Available

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04091295 2026-03-04

BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

Available

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Chordoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Neurofibrosarcoma